CIK 1907884
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 91.23% | 29 |
| Unclassified | 7.52% | 6 |
| Health Care Providers & Services | 1.26% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | SNDX | Syndax Pharmaceuticals Inc | Health Care | 11.94% |
| 2 | CLDX | Celldex Therapeutics, Inc. | Health Care | 11.76% |
| 3 | PCVX | Vaxcyte, Inc. | Health Care | 10.78% |
| 4 | COGT | Cogent Biosciences, Inc. | Health Care | 9.86% |
| 5 | VERA | Vera Therapeutics, Inc. | Health Care | 8.68% |
| 6 | BEAM | Beam Therapeutics Inc. | Health Care | 5.57% |
| 7 | CTMX | CytomX Therapeutics, Inc. | Health Care | 4.48% |
| 8 | BCRX | BIOCRYST PHARMACEUTICALS INC | Health Care | 3.43% |
| 9 | TVTX | Travere Therapeutics, Inc. | Health Care | 2.96% |
| 10 | VRDN | Viridian Therapeutics, Inc.\DE | Health Care | 2.91% |
30/36 names classified · sector 92.5% of weight · industry 92.5% · mkt cap 89.4%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 92.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 3% of book weight classified — the grid is NOT representative of the whole book.
Classified: 3.4% of book weight (1/33 names) · unclassified 96.6%: SNDX, CLDX, PCVX, COGT, VERA, , BEAM, CTMX, TVTX, VRDN +22 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | SNDXSYNDAX PHARMACEUTICALS INC | 8,050,959 | $188M | 11.9% | HOLD |
| 2 | CLDXCELLDEX THERAPEUTICS INC NEW | 5,840,567 | $185M | 11.8% | HOLD |
| 3 | PCVXVAXCYTE INC | 2,922,335 | $170M | 10.8% | HOLD |
| 4 | COGTCOGENT BIOSCIENCES INC | 4,037,331 | $155M | 9.9% | TRIM −35% |
| 5 | VERAVERA THERAPEUTICS INC | 3,398,224 | $137M | 8.7% | HOLD |
| 6 | BEAMBEAM THERAPEUTICS INC | 3,682,185 | $88M | 5.6% | ADD 51% |
| 7 | CTMXCYTOMX THERAPEUTICS INC. | 15,013,093 | $71M | 4.5% | ADD 67% |
| 8 | BCRXBIOCRYST PHARMACEUTICALS INC | 5,680,795 | $54M | 3.4% | TRIM −39% |
| 9 | TVTXTRAVERE THERAPEUTICS INC | 1,569,018 | $47M | 3.0% | ADD 203% |
| 10 | VRDNVIRIDIAN THERAPEUTICS INC | 2,341,652 | $46M | 2.9% | ADD 59% |
| 11 | CGEMCULLINAN THERAPEUTICS INC | 3,114,132 | $44M | 2.8% | HOLD |
| 12 | URGNUROGEN PHARMA LTD | 2,247,393 | $40M | 2.6% | NEW |
| 13 | KALVISTA PHARMACEUTICALS INC | 1,820,954 | $37M | 2.3% | HOLD |
| 14 | APELLIS PHARMACEUTICALS INC | 825,000 | $33M | 2.1% | TRIM −9% |
| 15 | LEGNLEGEND BIOTECH CORP | 1,576,295 | $29M | 1.8% | NEW |
| 16 | MBXMBX BIOSCIENCES INC | 934,799 | $28M | 1.8% | HOLD |
| 17 | IMCRIMMUNOCORE HLDGS PLC | 884,937 | $27M | 1.7% | ADD 3% |
| 18 | STROSUTRO BIOPHARMA INC | 872,558 | $22M | 1.4% | ADD 82% |
| 19 | BNRBURNING ROCK BIOTECH LTD | 1,227,555 | $20M | 1.3% | ADD 23% |
| 20 | SOLENO THERAPEUTICS INC | 560,000 | $19M | 1.2% | NEW |
| 21 | NRIXNURIX THERAPEUTICS INC | 1,194,757 | $19M | 1.2% | TRIM −39% |
| 22 | PHVSPHARVARIS N V | 640,395 | $18M | 1.1% | HOLD |
| 23 | EVMNEVOMMUNE INC | 625,496 | $14M | 0.9% | ADD 237% |
| 24 | RLAYRELAY THERAPEUTICS INC | 1,424,259 | $14M | 0.9% | HOLD |
| 25 | GERNGERON CORP | 6,836,318 | $10M | 0.6% | ADD 98% |
| 26 | ENGENE HOLDINGS INC | 1,356,843 | $9M | 0.6% | TRIM −9% |
| 27 | DSGNDESIGN THERAPEUTICS INC | 784,606 | $8M | 0.5% | HOLD |
| 28 | WVEWAVE LIFE SCIENCES LTD | 965,193 | $7M | 0.4% | TRIM −56% |
| 29 | CLYMCLIMB BIO INC | 1,003,341 | $7M | 0.4% | TRIM −2% |
| 30 | AMRNAMARIN CORP PLC | 472,382 | $7M | 0.4% | ADD 21% |
| 31 | BHVNBIOHAVEN LTD | 702,884 | $6M | 0.4% | HOLD |
| 32 | PRLDPRELUDE THERAPEUTICS INC | 1,592,551 | $5M | 0.3% | ADD 102% |
| 33 | CRBUCARIBOU BIOSCIENCES INC | 2,503,302 | $5M | 0.3% | HOLD |
| 34 | ALECALECTOR INC | 2,000,000 | $4M | 0.3% | HOLD |
| 35 | PRQRPROQR THRAPEUTICS N V | 1,566,317 | $3M | 0.2% | HOLD |
| 36 | CADLCANDEL THERAPEUTICS INC | 200,000 | $980,000 | 0.1% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| SNDXSYNDAX PHARMACEUTICALS INC | 8.5M | 8.5M | 8.5M | 8.5M | 8.1M | 8.1M | $188M |
| CLDXCELLDEX THERAPEUTICS INC NEW | 5.1M | 6.5M | 6.1M | 6.1M | 5.9M | 5.8M | $185M |
| PCVXVAXCYTE INC | 2.3M | 3.2M | 3.1M | 3.1M | 2.9M | 2.9M | $170M |
| COGTCOGENT BIOSCIENCES INC | 9.1M | 9.1M | 8.5M | 7.9M | 6.2M | 4.0M | $155M |
| VERAVERA THERAPEUTICS INC | 1.5M | 2.4M | 3.4M | 4.0M | 3.4M | 3.4M | $137M |
| BEAMBEAM THERAPEUTICS INC | 1.8M | 2.5M | 2.4M | 2.5M | 2.4M | 3.7M | $88M |
| CTMXCYTOMX THERAPEUTICS INC. | — | — | 2.2M | 3.6M | 9.0M | 15.0M | $71M |
| BCRXBIOCRYST PHARMACEUTICALS INC | 9.1M | 8.9M | 8.5M | 9.4M | 9.4M | 5.7M | $54M |
| TVTXTRAVERE THERAPEUTICS INC | 1.8M | 1.8M | 1.5M | 950K | 518K | 1.6M | $47M |
| VRDNVIRIDIAN THERAPEUTICS INC | 3.3M | 4.7M | 4.4M | 4.4M | 1.5M | 2.3M | $46M |
| CGEMCULLINAN THERAPEUTICS INC | 1.3M | 2.3M | 2.1M | 2.3M | 3.1M | 3.1M | $44M |
| URGNUROGEN PHARMA LTD | — | 25K | 657K | 282K | — | 2.2M | $40M |
| KALVISTA PHARMACEUTICALS INC | — | — | — | 606K | 1.8M | 1.8M | $37M |
| APELLIS PHARMACEUTICALS INC | — | — | — | 809K | 909K | 825K | $33M |
| LEGNLEGEND BIOTECH CORP | — | 610K | — | — | — | 1.6M | $29M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
